IDEAYA Prices Public Offering – A Milestone for Investors!

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is thrilled to announce the pricing of an underwritten public offering of common stock and pre-funded warrants! IDEAYA is offering 7,439,201 shares of common stock and pre-funded warrants to purchase 2,020,270 shares of common stock in the offering, at a public offering price of $18.50 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of $18.4999 per pre-funded warrant, with an exercise price of $0.0001 per share.

The underwriters also have a 30-day option to purchase up to an additional 1,418,920 shares of its common stock at the public offering price per share. The aggregate gross proceeds to IDEAYA from this offering are expected to be approximately $175,000,000, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants.

The anticipated closing date of this offering is April 27, 2023, pending the fulfillment of all customary closing conditions. Make sure to secure your stake before the deadline!

J.P. Morgan, Jefferies, and Citigroup are leading the charge as joint book-running managers for an upcoming offering, with RBC Capital Markets and Oppenheimer & Co. joining them as lead managers. Get ready to see these financial powerhouses in action!

IDEAYA is offering an exciting investment opportunity through a shelf registration statement filed and declared effective by the U.S. Securities and Exchange Commission. To access the details of this offer, you can request a written prospectus and prospectus supplement from J.P. Morgan. Simply mail your request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717. Don’t miss out on this chance to take advantage of this one-of-a-kind offer!

About IDEAYA Biosciences

At IDEAYA, we are taking precision medicine to the next level with our synthetic lethality-focused approach. By combining the power of identifying and validating translational biomarkers with the latest advances in drug discovery, we are creating targeted therapies that can be tailored to individual patient populations.

Our goal is to provide effective treatments that will improve the lives of those affected by cancer and other diseases. With our cutting-edge approach, we are making strides in the field of precision medicine and creating life-changing treatments for those in need.

Leave a Comment